| 1 |
34482636 | Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. | 2022 Jan |
1 |
| 2 |
34841430 | Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling. | 2022 Jan 1 |
1 |
| 3 |
34949839 | GCN2 kinase activation by ATP-competitive kinase inhibitors. | 2022 Feb |
1 |
| 4 |
35370966 | Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer. | 2022 |
2 |
| 5 |
33203645 | Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. | 2021 Mar 15 |
1 |
| 6 |
33414137 | Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. | 2021 Mar 15 |
1 |
| 7 |
33473169 | Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. | 2021 Mar |
2 |
| 8 |
34034468 | [Application of neratinib in the treatment of hormone receptor and HER-2 double positive breast cancer]. | 2021 May 23 |
1 |
| 9 |
34077739 | Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. | 2021 Aug |
1 |
| 10 |
34126793 | Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells. | 2021 Jul |
1 |
| 11 |
32862744 | Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. | 2020 Sep |
1 |
| 12 |
33013366 | The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer. | 2020 |
1 |
| 13 |
33019652 | Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer. | 2020 Oct 1 |
1 |
| 14 |
33843843 | Neratinib in the early-stage/extended adjuvant breast cancer patient. | 2020 Aug |
1 |
| 15 |
30183517 | Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition. | 2019 |
2 |
| 16 |
30203445 | Neratinib augments the lethality of [regorafenib + sildenafil]. | 2019 Apr |
1 |
| 17 |
30274983 | Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. | 2019 Jan 15 |
2 |
| 18 |
30321080 | Adverse cutaneous effects of neratinib. | 2019 Aug |
2 |
| 19 |
30370488 | Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials. | 2019 Jan |
1 |
| 20 |
30500458 | Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. | 2019 Jan |
1 |
| 21 |
30571927 | Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells. | 2019 |
1 |
| 22 |
30607817 | Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU. | 2019 Feb |
4 |
| 23 |
30607980 | Neratinib in HER2-Positive Breast Cancer Patients. | 2019 Jun |
2 |
| 24 |
31253872 | Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. | 2019 Jul |
5 |
| 25 |
31254668 | A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. | 2019 Nov |
1 |
| 26 |
31286784 | Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors. | 2019 Dec |
2 |
| 27 |
31380285 | The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib. | 2019 |
2 |
| 28 |
31676778 | Neratinib protects pancreatic beta cells in diabetes. | 2019 Nov 1 |
1 |
| 29 |
29219657 | The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. | 2018 Feb 1 |
4 |
| 30 |
29333953 | The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. | 2018 Mar 4 |
3 |
| 31 |
29405820 | The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. | 2018 Jun 3 |
3 |
| 32 |
29426804 | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). | 2018 Jun |
1 |
| 33 |
29645336 | Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells. | 2018 Jun 11 |
1 |
| 34 |
29880014 | Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. | 2018 Jun 8 |
1 |
| 35 |
30323297 | Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level. | 2018 Oct 15 |
1 |
| 36 |
30466991 | Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. | 2018 Nov 15 |
1 |
| 37 |
32914002 | Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. | 2018 |
4 |
| 38 |
27907855 | LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma. | 2017 Feb 5 |
2 |
| 39 |
28487443 | HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. | 2017 Sep 1 |
2 |
| 40 |
28744140 | Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. | 2017 |
1 |
| 41 |
28744399 | The addition of calcitriol or its synthetic analog EB1089 to lapatinib and neratinib treatment inhibits cell growth and promotes apoptosis in breast cancer cells. | 2017 |
1 |
| 42 |
28766379 | Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis. | 2017 Oct |
1 |
| 43 |
28884417 | Neratinib: First Global Approval. | 2017 Oct |
4 |
| 44 |
28969097 | Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients. | 2017 Sep 8 |
1 |
| 45 |
29163826 | HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo. | 2017 Oct 27 |
2 |
| 46 |
26834058 | Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. | 2016 Mar 20 |
1 |
| 47 |
26874901 | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. | 2016 Mar |
1 |
| 48 |
27405796 | Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor. | 2016 Oct |
3 |
| 49 |
27920501 | Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer. | 2016 |
1 |
| 50 |
26018524 | Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. | 2015 |
1 |